Previous 10 | Next 10 |
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been i...
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Of...
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each...
2024-03-19 09:19:52 ET Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. Th...
2024-03-13 13:24:05 ET ADC Therapeutics SA (ADCT) Q4 2023 Results Earnings Conference Call March 13, 2024, 08:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-...
2024-03-13 07:04:51 ET More on ADC Therapeutics ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial ADC Therapeutics regains compliance with NYSE continued listing standards Seeking Alpha’s Quant Rating on ADC Therapeutics Historical earning...
SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for...
2024-03-12 10:52:51 ET More on ADC Therapeutics ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial ADC Therapeutics regains compliance with NYSE continued listing standards Seeking Alpha’s Quant Rating on ADC Therapeutics Historical earning...
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT. A live webc...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...